These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. Gordon MK; Sher D; Karrison T; Kebriaei P; Chuang K; Zhang Y; McDonnell D; Artz A; Godley L; Odenike O; Rich E; Michaelis L; Thirman MJ; Wickrema A; van Besien K; Larson RA; Stock W Leuk Lymphoma; 2008 Mar; 49(3):531-7. PubMed ID: 18297531 [TBL] [Abstract][Full Text] [Related]
5. Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate. Perseghin P; Gambacorti-Passerini C; Tornaghi L; Dassi M; Pioltelli P; Parma M; Colnaghi F; Giudici G; Elli E; Fumagalli M; Ponchio L; Biondi A; Pogliani EM Transfusion; 2005 Jul; 45(7):1214-20. PubMed ID: 15987369 [TBL] [Abstract][Full Text] [Related]
6. Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. Bashir Q; De Lima MJ; McMannis JD; Garcia-Manero G; Shpall E; Kantarjian H; Cortes JE; O'Brien SM; Jones D; Qazilbash M; Wei W; Giralt SA; Champlin RE; Hosing C Leuk Lymphoma; 2010 Aug; 51(8):1478-84. PubMed ID: 20658954 [TBL] [Abstract][Full Text] [Related]
7. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765 [TBL] [Abstract][Full Text] [Related]
8. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408 [TBL] [Abstract][Full Text] [Related]
9. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666 [TBL] [Abstract][Full Text] [Related]
10. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334 [TBL] [Abstract][Full Text] [Related]
11. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate. Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919 [TBL] [Abstract][Full Text] [Related]
12. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia. Wang L; Pearson K; Pillitteri L; Ferguson JE; Clark RE Br J Haematol; 2002 Sep; 118(3):771-7. PubMed ID: 12181044 [TBL] [Abstract][Full Text] [Related]
13. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Press RD; Love Z; Tronnes AA; Yang R; Tran T; Mongoue-Tchokote S; Mori M; Mauro MJ; Deininger MW; Druker BJ Blood; 2006 Jun; 107(11):4250-6. PubMed ID: 16467199 [TBL] [Abstract][Full Text] [Related]
14. Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse. Kim YJ; Kim DW; Lee S; Min CK; Goh HG; Kim SH; Lee JY; Kim YL; Kim HJ; Kim HJ; Lee JW; Kim TG; Min WS; Kim CC Biol Blood Marrow Transplant; 2004 Oct; 10(10):718-25. PubMed ID: 15389438 [TBL] [Abstract][Full Text] [Related]
15. Mobilization of Ph chromosome-negative peripheral blood stem cells in a child with chronic myeloid leukemia after imatinib-induced complete molecular remission. Woods-Swafford W; Vnencak-Jones CL; Loken MR; Manes B; Frangoul H Pediatr Blood Cancer; 2008 Mar; 50(3):639-41. PubMed ID: 16927371 [TBL] [Abstract][Full Text] [Related]
16. Detection of trisomy 8 in donor-derived Ph- cells in a patient with Ph+ chronic myeloid leukemia successfully treated with Imatinib (STI571) in relapse after allogeneic transplantation. Agis H; Mannhalter C; Sperr WR; Keil F; Kalhs P; Pirc-Danoewinata H; Krauth MT; Haas OA; Geissler K; Lechner K; Valent P Leuk Lymphoma; 2004 Jul; 45(7):1453-8. PubMed ID: 15359647 [TBL] [Abstract][Full Text] [Related]
17. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Wang L; Pearson K; Ferguson JE; Clark RE Br J Haematol; 2003 Mar; 120(6):990-9. PubMed ID: 12648069 [TBL] [Abstract][Full Text] [Related]
18. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Chu S; Xu H; Shah NP; Snyder DS; Forman SJ; Sawyers CL; Bhatia R Blood; 2005 Mar; 105(5):2093-8. PubMed ID: 15345592 [TBL] [Abstract][Full Text] [Related]
19. Collection of Philadelphia-negative stem cells using recombinant human granulocyte colony-stimulating factor in chronic myeloid leukemia patients treated with alpha-interferon. Hernández-Boluda JC; Carreras E; Cervantes F; Marín P; Arellano-Rodrigo E; Rovira M; Solé F; Lloveras E; Espinet B; Ocejo A; Montserrat E Haematologica; 2002 Jan; 87(1):17-22. PubMed ID: 11801461 [TBL] [Abstract][Full Text] [Related]
20. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR]. Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]